Literature DB >> 1824776

Characterization of a membrane antigen of Leishmania amazonensis that stimulates human immune responses.

J M Burns1, J M Scott, E M Carvalho, D M Russo, C J March, K P Van Ness, S G Reed.   

Abstract

To investigate human immune responses to defined leishmania Ag we have begun to characterize biochemically and immunologically, an abundant 42-kDa surface Ag of Leishmania amazonensis, a causative agent of human leishmaniasis. We have shown that this Ag, La gp42, is expressed on the surface of L. amazonensis promastigotes, being anchored to the membrane by a glycosyl-phosphatidylinositol moiety. As demonstrated by lectin blotting studies, La gp42 is glycosylated, binding both Con A and wheat germ agglutinin. Immunologically, La gp42 is strongly recognized by sera from patients with different forms of leishmaniasis as well as by patients with Chagas' disease. In addition, we show that purified La gp42 stimulates the proliferation of human T lymphocytes obtained from several leishmaniasis patients. Finally, the N-terminal sequence of La gp42 was obtained and a serologically cross-reactive 42-kDa protein with a homologous sequence was identified in Leishmania major.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1824776

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

1.  Immunostimulatory cellular responses of cured Leishmania-infected patients and hamsters against the integral membrane proteins and non-membranous soluble proteins of a recent clinical isolate of Leishmania donovani.

Authors:  R Garg; S K Gupta; P Tripathi; S Naik; S Sundar; A Dube
Journal:  Clin Exp Immunol       Date:  2005-04       Impact factor: 4.330

Review 2.  The development and clinical evaluation of second-generation leishmaniasis vaccines.

Authors:  Malcolm S Duthie; Vanitha S Raman; Franco M Piazza; Steven G Reed
Journal:  Vaccine       Date:  2011-11-12       Impact factor: 3.641

3.  Disparate immunoregulatory potentials for double-negative (CD4- CD8-) alpha beta and gamma delta T cells from human patients with cutaneous leishmaniasis.

Authors:  Lis R V Antonelli; Walderez O Dutra; Ricardo R Oliveira; Karen C L Torres; Luiz H Guimarães; Olivia Bacellar; Kenneth J Gollob
Journal:  Infect Immun       Date:  2006-08-21       Impact factor: 3.441

4.  A protective glycosylphosphatidylinositol-anchored membrane protein of Plasmodium yoelii trophozoites and merozoites contains two epidermal growth factor-like domains.

Authors:  J M Burns; C C Belk; P D Dunn
Journal:  Infect Immun       Date:  2000-11       Impact factor: 3.441

5.  Recombinant vaccinia viruses expressing GP46/M-2 protect against Leishmania infection.

Authors:  D McMahon-Pratt; D Rodriguez; J R Rodriguez; Y Zhang; K Manson; C Bergman; L Rivas; J F Rodriguez; K L Lohman; N H Ruddle
Journal:  Infect Immun       Date:  1993-08       Impact factor: 3.441

Review 6.  Leishmaniases of the New World: current concepts and implications for future research.

Authors:  G Grimaldi; R B Tesh
Journal:  Clin Microbiol Rev       Date:  1993-07       Impact factor: 26.132

7.  A recombinant Leishmania chagasi antigen that stimulates cellular immune responses in infected mice.

Authors:  M E Wilson; B M Young; K P Andersen; J V Weinstock; A Metwali; K M Ali; J E Donelson
Journal:  Infect Immun       Date:  1995-05       Impact factor: 3.441

8.  Antigens shared by Leishmania species and Trypanosoma cruzi: immunological comparison of the acidic ribosomal P0 proteins.

Authors:  Y A Skeiky; D R Benson; M Elwasila; R Badaro; J M Burns; S G Reed
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

9.  Molecular characterization of a kinesin-related antigen of Leishmania chagasi that detects specific antibody in African and American visceral leishmaniasis.

Authors:  J M Burns; W G Shreffler; D R Benson; H W Ghalib; R Badaro; S G Reed
Journal:  Proc Natl Acad Sci U S A       Date:  1993-01-15       Impact factor: 11.205

10.  Evaluation of Leishmania donovani protein disulfide isomerase as a potential immunogenic protein/vaccine candidate against visceral Leishmaniasis.

Authors:  Pramod Kumar Kushawaha; Reema Gupta; Chandra Dev Pati Tripathi; Shyam Sundar; Anuradha Dube
Journal:  PLoS One       Date:  2012-04-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.